Thierry M. Jahan is a highly regarded thoracic oncologist who is board-certified in medical oncology, hematology and internal medicine, and is specialized in mesothelioma.
- Co-founded hospital’s Thoracic Oncology Program.
- Known for great empathy and compassion.
- Research interest in testing target therapies in non-small cell lung cancer malignant mesothelioma as either single agents or in combination with chemotherapy and/or radiation.
- Currently investigating a drug (PTK787/ZK 222584) that may offer hope to patients with unresectable malignant mesothelioma by blocking the enzymes necessary for tumor cell growth.
- Written numerous peer-reviewed articles, book chapters and research abstracts; principal author of a 2012 article in the journal Lung Cancer reporting on findings of a multicenter phase II trial to evaluate the efficacy and safety of chemotherapy drug vatalanib against malignant mesothelioma.
- Lectured internationally on mesothelioma; sought out by print and broadcast news outlets for his insights concerning the clinical and human side of fighting mesothelioma.
- Teaches at University of California at San Francisco School of Medicine.
- Honors include winning the Medical House Staff Outstanding Teacher and Friend of the Palliative Care Service awards.
- Member of the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer, and Association of Northern California Oncologists.
- M.D. degree from George Washington University School of Medicine.